tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Day One reports preliminary FY25 Ojemda net product revenue of $155.4M
PremiumThe FlyDay One reports preliminary FY25 Ojemda net product revenue of $155.4M
7d ago
Day One Biopharmaceuticals: Ojemda Outperformance and Catalyst-Rich Pipeline Underpin Buy Rating
Premium
Ratings
Day One Biopharmaceuticals: Ojemda Outperformance and Catalyst-Rich Pipeline Underpin Buy Rating
7d ago
3 Stocks with a ‘Perfect 10’ Smart Score
Premium
Market News
3 Stocks with a ‘Perfect 10’ Smart Score
12d ago
Day One Biopharmaceuticals Reveals Promising Phase 2 Trial Results
PremiumCompany AnnouncementsDay One Biopharmaceuticals Reveals Promising Phase 2 Trial Results
2M ago
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential
Premium
Ratings
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential
2M ago
Promising Clinical Results and Growth Potential Reinforce Buy Rating for Day One Biopharmaceuticals’ Ojemda
Premium
Ratings
Promising Clinical Results and Growth Potential Reinforce Buy Rating for Day One Biopharmaceuticals’ Ojemda
2M ago
Oppenheimer says Day One paying up to $285M for Mersana ‘is interesting’
PremiumThe FlyOppenheimer says Day One paying up to $285M for Mersana ‘is interesting’
2M ago
Strategic Acquisition of Mersana Therapeutics Boosts Day One Biopharmaceuticals’ Oncology Pipeline
Premium
Ratings
Strategic Acquisition of Mersana Therapeutics Boosts Day One Biopharmaceuticals’ Oncology Pipeline
2M ago
Why Is Mersana Therapeutics Stock (MRSN) Up Today?
Premium
Market News
Why Is Mersana Therapeutics Stock (MRSN) Up Today?
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100